[54] SYNERGISTIC ADMINISTRATION OF CYCLOSPORINE AND FRUCTOSE DIPHOSPHATE
[76] Inventor: Angel K. Markov, 5973 Hanging Moss Rd., Jackson. Miss. 39206
[21] Appl. No.: 280,374
[22] Filed: Jul. 26,1994
[51] IntCI.6 A61K 31/70
[52] U.S. Cl 514/23; 514/9; 514/25;
514/885; 514/922; 530/317
[58] Field of Search 514/23,9,25,
514/885, 922; 530/317
[56] References Cited
U.S. PATENT DOCUMENTS
4,448,771 5/1984 Cattanietal 424/180
4,546,095 10/1985 Markov 514/23
4,757,052 7/1988 Markov 514/23
5,039,665 8/1991 Markov 514/23
5,196,402 3/1993 Braganza et al 514/46
This invention discloses a method of using fructose-1.6diphosphate (FDP) to help suppress the rejection of internal organs such as kidneys, hearts, etc. At least three major advantages of FDP in conjunction with organ transplants have ^^ identified: (1) FDP can help reduce the unwanted proliferation of certain types of stimulated lymphocytes which would otherwise pose a risk of attacking the non-self cells in the transplanted organ; (2) FDP can also potentiate me effectiveness of cyclosporine as a transplant-protecting immunosuppressant, thereby allowing a reduction in CSA dosages, which in turn can reduce the likelihood and the severity of toxic side effects and other dangers of CSA treatment; (3) FDP can also reduce the amount of damage n an organ during the removal and storage steps
88
